Applied DNA Sciences (NASDAQ:APDN – Get Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday.
A number of other analysts also recently issued reports on APDN. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Applied DNA Sciences in a report on Friday, February 10th. Maxim Group cut their target price on Applied DNA Sciences from $6.00 to $3.00 in a research report on Friday, December 16th.
Applied DNA Sciences Stock Up 0.9 %
Shares of NASDAQ APDN opened at $1.08 on Monday. The business has a 50-day moving average of $1.54 and a two-hundred day moving average of $1.70. Applied DNA Sciences has a 1 year low of $0.62 and a 1 year high of $7.35.
Institutional Trading of Applied DNA Sciences
About Applied DNA Sciences
Applied DNA Sciences, Inc engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment consists of the manufacture of DNA for use in nucleic acid-based therapeutics.
- Get a free copy of the StockNews.com research report on Applied DNA Sciences (APDN)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Receive News & Ratings for Applied DNA Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied DNA Sciences and related companies with MarketBeat.com's FREE daily email newsletter.